NSE:INFY.NS News 17 January 2026

January 23, 2026, 12:15 PM EST. 10x Genomics (TXG) has seen a recent share price surge with a 40.55% increase over one month and a 68.41% rise in 90 days, driven by investor interest in genomics tools. Despite this momentum, the stock trades at $23.19, above the average analyst price target of $18.23 and a narrative-based fair value of $17.36, suggesting possible overvaluation. The company's acquisition of Scale Biosciences enhances its single-cell analysis capabilities, potentially boosting future revenue and margins. Risks remain, including reduced research funding and pricing pressures that may affect growth expectations. Investors are urged to weigh these factors as 10x Genomics' long-term total shareholder returns have been weaker. The stock's elevated price demands careful consideration of the underlying growth story and market assumptions.